Trials / Withdrawn
WithdrawnNCT02941601
A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-naïve participants with locally advanced or metastatic squamous non-small cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Necitumumab | Administered IV |
| DRUG | Gemcitabine | Administered IV |
| DRUG | Carboplatin | Administered IV |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-12-01
- Completion
- 2019-02-01
- First posted
- 2016-10-21
- Last updated
- 2019-09-27
Locations
19 sites across 7 countries: United States, Belgium, Germany, Italy, Romania, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT02941601. Inclusion in this directory is not an endorsement.